Versant Ventures leads $12 mln Series A funding round in AAVLife
Versant Ventures has led a $12 million Series A funding round in AAVLife, a gene therapy company focusing on rare diseases. Inserm Transfert Initiative, a French seed investment firm, participated in the funding round.
15 April 2014•5 mins read
